July 19, 2011
New Therapies for African HIV Patients
(Ivanhoe Newswire) -- A landmark study by the BC Centre for Excellence in HIV/AIDS (BC-CfE) and the University of British Columbia (UBC) shows that patients in Africa receiving combination antiretroviral therapy (cART) for HIV can expect to live a near normal lifespan.
The study is the first large-scale analysis of life expectancy outcomes in Africa for HIV patients on cART and shows significant variance between patient subgroups. Females have a significantly higher life expectancy than men, and in all participants, early initiation of treatment was associated with longer life expectancy."The substantial life expectancy afforded by widespread access to cART underscores the fact that HIV diagnosis and treatment in resource-limited settings should no longer be considered a death sentence," principal investigator Dr. Edward Mills, associate researcher at the BC-CfE and an adjunct professor in UBC's Faculty of Medicine, was quoted as saying. "Instead, HIV-infected people should plan and prepare for a long and fulfilling life."
The authors believe that the study, conducted in Uganda, reflects the situation in many other settings in Africa, where simplified HIV/AIDS care in rural, semi-rural and urban settings is available.
"Our findings are further evidence that the global investment in HIV and AIDS programming is clearly working," Dr. Mark Dybul, a study author who led the implementation of U.S. President's Emergency Plan for AIDS Relief (PEPFAR) from 2006-2009 and is now at Georgetown University and the George W. Bush Institute, was quoted as saying. "Healthcare organizations "“ even in resource-poor settings "“ are providing services and therapies that offer important, life-saving benefits to people suffering from HIV."
The study analyzed a cohort of 22,315 individuals aged 14 or older, who initiated cART at The AIDS Support Organization (TASO) clinics between 2000 and 2009. In Uganda, life expectancy at birth is approximately 55 years and increases as individuals survive key milestones. Life expectancy at age 20 years for the overall study cohort on cART was an additional 26.7 years and at age 35 an additional 27.9 years.
Males showed consistently lower life expectancy than females. Life expectancy at age 20 years was 19.1 years for males and 30.6 years for females, and at age 35 years was 22 years for males and 32.5 years for females. Men typically access care at a later stage, with more advanced disease, and have higher rates of mortality than females. "Men remain one of our huge challenges in terms of access to clinical services," said Mills.
The study found a strong association between baseline CD4 cell status and mortality when controlling for factors such as age, year of cART initiation and gender. Those who started cART earlier, at a higher CD4 cell status, lived longer.
"These benefits will only be sustained if there is continued support for cART scale up by the international donor community and national governments," study author Dr. Jean Nachega, Professor of Medicine and director of the Centre for Infectious Diseases at Stellenbosch University, Cape Town, South Africa, was quoted as saying. "We require sustainable investment and simplified treatment options to deliver long-term care and access more people in Africa with HIV."
SOURCE: Annals of Internal Medicine, published online July 18, 2011